ALK and non-small cell lung carcinoma: More than 20 NTRK1, NTRK2, and NTRK3 fusion partners have been identified in NSCLC (13), which usually do not coexist with other oncogenic drivers, such as EGFR, ALK, ROS1, MET, and RET (14).